Actually the 10Q indicates the opposite the lab lost net-net income. Irrespective of this because the loss was insignificant explain how the lab will contribute meaningful earnings. Einstein.
News flash: Cepheid was acquired by Danaher for $53/sh. The question remains why acquire another "me too" business in a market sector that is savaged from competition of larger scale labs, declining asking pricing and capex expenses hurting the bottom line.
The Dr. really screwed up on this one.
Common, you can' t be serious! BIIB owns the ms market with R&D to support new pharmacological agents. OPK on the other hand grows by acquisition mode only. Sort of the way Valeant approaches the market.
There's the quick and easy recipe to be slaughtered having a majority of your investment $'s in a speculative play. Pure emotional investing.
Of all the thousands of securities listed on the exchanges there nowhere else to invest? Really ?
Neither of you have any grasp of the Theranos technology. The testing of endocrine compounds at ppb sample size is so incredibly dicey. So the interpretation of the testing protocol is open to many opinions. This should answer why Claros has a very long road ahead for approval and adoption.
I would say that Holmes is both a visionary and entrepreneur.
When you analyze the reasons for the BRLI acquisition, the bottom line will be the success of 4k adoption. On its own merits as a stand alone operation, the lab analytical business is capital intensive, modest margins., varied and diverse competition.
The argument of now having a ready trained sales force is economically misguided.
Another compelling reason for a CEO while leaving the Dr . at the Chairman's position. This re-alignment should allow him the time to do what he does so well: find opportunities to grow the pipeline.
O.T.: Not only is your language disgraceful, but also your stock movement analysis is without even a smidgeon of redeeming quality.
Back to the corner with your dunce cap
We agree on the merits of Chanos', but I believe that you're ignoring the influence of the BRLI dilution. If it was for the sales reps to call on the medical community for 4K testing, alternative sales channels were available.
The lab business is a cut throat business with high cap-ex and little pricing power.
Greater revenue and earning texture during the next earnings is a must.